Israel Englander’s INmune Bio INMB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$260K Buy
+159,559
New +$221K ﹤0.01% 5185
2025
Q3
Sell
-42,612
Closed -$98.4K 6226
2025
Q2
$98.4K Sell
42,612
-198,636
-82% -$1.46M ﹤0.01% 5517
2025
Q1
$1.88M Sell
241,248
-50,079
-17% -$398K ﹤0.01% 3835
2024
Q4
$1.36M Buy
291,327
+88,823
+44% +$463K ﹤0.01% 3951
2024
Q3
$1.09M Buy
202,504
+109,834
+119% +$781K ﹤0.01% 4200
2024
Q2
$817K Sell
92,670
-66,522
-42% -$656K ﹤0.01% 4244
2024
Q1
$1.87M Buy
159,192
+134,988
+558% +$1.63M ﹤0.01% 3808
2023
Q4
$273K Buy
+24,204
New +$203K ﹤0.01% 5010
2023
Q3
Sell
-28,146
Closed -$256K 6328
2023
Q2
$256K Buy
28,146
+10,525
+60% +$84.5K ﹤0.01% 4993
2023
Q1
$114K Buy
17,621
+989
+6% +$7.96K ﹤0.01% 5379
2022
Q4
$105K Sell
16,632
-10,537
-39% -$74.8K ﹤0.01% 5566
2022
Q3
$168K Buy
+27,169
New +$239K ﹤0.01% 5753
2022
Q1
Sell
-150,680
Closed -$1.54M 7167
2021
Q4
$1.54M Buy
150,680
+27,169
+22% +$402K ﹤0.01% 4008
2021
Q3
$2.4M Buy
+123,511
New +$2.38M ﹤0.01% 3699
2021
Q2
Sell
-41,988
Closed -$499K 6767
2021
Q1
$499K Buy
+41,988
New +$756K ﹤0.01% 4827

Other funds holding INMB

Israel Englander's INMB Position: Q2 2026 in Review

Israel Englander opened a new position in INmune Bio (INMB) in Q2 2026: 159,559 shares worth $260K. The stake represents ﹤0.01% of the portfolio and ranks #5185 among its holdings. This is a return to the name: Israel Englander previously reported a position in INMB as recently as Q2 2025.

Israel Englander first reported a position in INMB in Q1 2021 and has held it in 15 quarters since. The position peaked at $2.4M in Q3 2021. 83 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

  • Israel Englander held 159,559 shares of INmune Bio worth $260K as of Q2 2026.
  • INmune Bio was a new Israel Englander position in Q2 2026.
  • INmune Bio made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #5185 holding.
  • Israel Englander first reported a position in INmune Bio in Q1 2021 and has held it in 15 quarters since.
  • Israel Englander's INmune Bio position peaked at $2.4M in Q3 2021.
  • 83 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.